Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 103 clinical trials
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma

This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without ruxolitinib phosphate in treating patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that has come back or …

line of therapy
ct scan
tumor cells
neutrophil count
  • 21 Mar, 2022
  • 2 locations
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by …

sezary syndrome
large cell lymphoma
autologous transplant
treatment regimen
  • 25 May, 2022
  • 1 location
Multimodal Morpho-functional Study in Glaucoma Patients-Citicoline Oral Solution

A prospective, multicentre, randomized, blinded, masked study that involves the enrollment of 60 patients affected by open angle glaucoma (OAG). Patients selected according to the inclusion / exclusion criteria, after signing the informed consent, will be randomized into two groups: In a group of patients with OAG, Citicoline in oral …

beta blockers
carbonic anhydrase inhibitors
  • 19 Apr, 2022
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, …

sezary syndrome
extramammary paget's disease
mucinous carcinoma
  • 10 Oct, 2022
  • 6 locations
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm

This phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacytidine, work in different …

essential thrombocythemia
neutrophil count
direct bilirubin
  • 04 Oct, 2022
  • 1 location
Actuate 1901: 9-ING-41 in Myelofibrosis

9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study its efficacy in patients with advanced myelofibrosis.

stem cell transplantation
neutrophil count
  • 13 May, 2022
  • 9 locations
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.

  • 01 Mar, 2021
  • 1 location
A Safety and Tolerability Study of Jaktinib

This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.

  • 04 Oct, 2022
  • 1 location
A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Subjects With Relapsed or Refractory Hematological Malignancies

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 subjects.

neutrophil count
refractory acute myeloid leukemia (aml)
refractory multiple myeloma
  • 25 Oct, 2022
  • 5 locations
Optimizing Protein Patterns for Skeletal Muscle Preservation and Sleep in the Medical Management of Parkinson Disease

The purpose of this pilot study is to generate preliminary data on the impact of the dietary protein pattern on markers of skeletal muscle health and drug efficacy in Parkinson disease.

  • 22 Oct, 2022
  • 1 location